Agency Interactions

PharmaLex has long-standing and extensive experience on agency interactions with the scientific committees and working parties of the EMA (e.g. CHMP, PRAC, COMP, PDCO, CAT) and with national Health Authorities. We frequently support our clients in Scientific Advice procedures at a national or central level, and in numerous health authority interactions throughout a product’s lifecycle (e.g. requests for PRIME eligibility, Orphan Medicinal Product designations, Pediatric Investigational Plans, Marketing Authorization Applications).

Contact our specialists to tailor a service plan

    Add a header to begin generating the table of contents

    Ensuring regulatory success

    Meetings with Health Authorities such as the FDA in the US, the EMA in Europe or other major Health Authorities worldwide have shown to increase the probability of market approval and can have a most favorable impact on development times and costs. Since Health Authorities make the final decision to approve or reject products, it is highly recommended to optimize authority communication and to hold face-to-face and teleconference meetings all along the development pathway. But how do you get the best out of your meeting with a Health Authority?

    Authorities encourage to start discussions as early in the development process as possible so that developers can become aware of risks and weaknesses of their development plans to address them in a timely fashion. Meetings at critical milestones during development have been shown to dramatically increase the probability of timely approval.

    In the US, PharmaLex frequently engages with the FDA and has managed numerous of meetings with different FDA divisions for our clients (e.g. for pre-IND, End of Phase 2, pre-NDA or Type C meetings) or interacted with them in other drug development and authorization related procedures.

    Similarly, PharmaLex supports interactions with other major Health Authorities worldwide, facilitated by our local country-based affiliates and partners who can provide local procedural guidance and logistical support.

    We offer global solutions covering the entire product lifecycle

     Our solutions, consisting of core services, which are tailored to address each of your unique requirements. Extensive program management expertise is a key success factor within our service solutions.

    We make you aware what Health Authorities pay attention to, what kind of inquiries they make and what they expect to hear from applicants.

    • Proven track record (last five years)
      • > 75   Scientific Advices
      • > 25   Pediatric Investigational Plans (PIP)
      • > 15   Orphan Medicinal Product (OMP) designations
        5   Advanced Therapy Medicinal Product (ATMP) classifications
        5   PRIME eligibility and Innovation Task Force (ITF) meetings
        3   Adaptive Pathway eligibility applications
      • > 10   CP Pre-Submission and Rapporteur meetings
    • Supporting all aspects of meeting preparation
      • Advice: We help to decide on the strategy of approaching regulatory health authorities and which questions to ask.
      • Documentation: We provide support to compile a briefing package including all necessary documentation.
      • Coaching: We train your meeting delegates to ask the right questions and to obtain relevant answers.
      • Meeting: We attend and/or lead the meeting with the Health Authority on behalf of the client facilitating the meeting discussion.
      • Response: We use our regulatory expertise and experience to interpret health authority requests and recommendations.
      • Implementation: We support project teams to adequately and timely address the advice received.

    Meetings with Health Authorities are highly valuable opportunities to consolidate and optimize your development strategy with the input of the future decision makers on your marketing authorization application. Opportunities for direct interactions with regulators are still limited though nowadays all major authorities offer regulatory and scientific advice meetings. To get the best out of them, they must be well prepared.

    PharmaLex has extensive experience of leading clients through the Scientific Advice process. We frequently support centralized Scientific Advice process at the SAWP/CHMP or national Health Authorities. In addition, we support our clients interacting with all scientific committees and working parties of the EMA (e.g. CHMP, PRAC, COMP, PDCO, CAT).

    As part of its regulatory service offering, PharmaLex has had extensive experience representing clients at FDA regulatory meetings and regulatory advice communications. We have worked with clients across all stages of development, from discussing IND readiness at pre-IND meetings, clarifying critical developmental questions at Type C meetings, and have assisted clients with halted development programs at Type A meetings as well as supporting later-stage development at End of Phase 2 and pre-NDA meetings. PharmaLex has also assisted clients at Biosimilar Biological Product Development (BPD) meetings from Biosimilar initial advisory meeting (BIA) to BDP Type 1-4) to support biosimilar product development in the US.

    PharmaLex’s expertise is not limited to specific divisions or indications, as we have interacted with nearly every division at the FDA, including specialized units such as the Division of Clinical Outcome Assessment (DCOA, formerly SEALD) and office of orphan product development (OOPD).

    PharmaLex offers support during all aspects of the meeting process, from assisting with meeting strategy, through authorship, review, and submission of meeting-related documents, Sponsor meeting preparation, FDA meeting attendance, and follow-up activities. PharmaLex prides itself in understanding the goals of the client and identifying appropriate strategies for both effectively communicating with the FDA and fostering a collaborative relationship with the Agency, thereby resulting in efficient product development often saving Sponsors time and money.

    • Proven track record
      • Just in the last 5 years (2015-2020) supported 60+ FDA meetings, including pre-IND, End of Phase 1 and 2, Pre-NDA, Type C, Type A, and Biosimilar (BIA, BPD 1, 2 and 3) Meetings, ANDA controlled correspondence and Pre-ANDA meetings.
    • Diverse experience portfolio
      • Experience spans small and large (polymers) molecules, biologics including CGT, regenerative medicine, recombinant proteins, biosimilars, and combination products
      • Expertise working with multiple FDA review divisions across both CDER and CBER, supporting numerous indications at various stages of development
      • Expertise in various therapeutic areas such as rare diseases, advanced therapies, acute and chronic pain, CNS disease, oncology, and gastrointestinal disorders providing a wide range of experience to support multiple different types of programs
    • Ability to support all aspects of meeting preparation and related activities
      • Substantial experience in assisting clients with FDA meeting strategy, formulating thoughtful meeting discussion topics, designed to maximize meeting opportunity, leading to efficient development programs
      • Significant experience with authorship and submission of required meeting materials, including meeting requests and briefing documents, in compliance with FDA guidelines, to ensure FDA is well informed of the Sponsor’s program and developmental strategy to support meeting discussion
      • Able to prepare and lead meeting rehearsals to certify all attendees are well prepared prior to meeting with the Agency, including assisting with the overall messaging strategy to support the Sponsor’s goals of the meeting
      • Ability to attend and/or lead FDA meetings on behalf of the Sponsor, assisting with the facilitation of the meeting discussion and fostering collaboration with the FDA

    Aiding and steering of follow-up activities and interactions occurring from the FDA meeting including authorship and submission of meeting minutes and developing appropriate program strategy based on FDA meeting discussion.

     

    As part of its regulatory service offering, PharmaLex has had extensive experience representing clients at FDA regulatory meetings and regulatory advice communications. We have worked with clients across all stages of development, from discussing IND readiness at pre-IND meetings, clarifying critical developmental questions at Type C meetings, and have assisted clients with halted development programs at Type A meetings as well as supporting later-stage development at End of Phase 2 and pre-NDA meetings. PharmaLex has also assisted clients at Biosimilar Biological Product Development (BPD) meetings from Biosimilar initial advisory meeting (BIA) to BDP Type 1-4) to support biosimilar product development in the US.

    Available Resources

    Related Services

    With over 75 CMC consultants across the globe, PharmaLex has substantial CMC expertise across all areas. We are able to offer an integrated solution combining the scientific, technological, non-clinical, clinical and regulatory expertise with our broad global project experience to meet your specific needs, from discovery to licensing and post-approval.

    More Info

    CMC strategy and documentation plays an important role from early development to authoring of the marketing authorization application dossier. It also extends to change control and maintenance throughout the product lifecycle. Moreover, CMC requirements are complex and different for chemicals, biologicals, biosimilars, herbals or homeopathics. PharmaLex guides you to the best CMC approach for your products in line with health authority requirements and helps you to stay CMC compliant with sustainable processes.

    More Info

    Ensuring a smooth and effective submission process today goes beyond the old ways of eCTD publishing. For over 15 years, we have led the way in regulatory submissions with an evolving holistic approach that includes everything from planning to embedded quality control. Of course, all of our services are complemented by state-of-the-art digital facilitation.

    More Info

    Whether you are interested in outsourcing portfolio maintenance, require support during a merger and acquisition phase, need assistance covering your pharmacovigilance obligations or in development and implementation of your QMS—our Post-approval solutions provide trusted, strategic ways, as well as hands-on support, to keep your product compliant and moving forward.

    More Info

    PharmaLex offers scientific, regulatory and technical writing, supporting clients in the development of medicinal products.

    More Info

    Contact Us

    Contact Form

    Complete this form to stay in contact with us.

    Global Approach

    PharmaLex has 60+ offices in 32 countries serving more than 1600 satisfied clients worldwide. Search your nearest office.

    Scroll to Top